DelMar Pharmaceuticals Inc  

(Public, NASDAQ:DMPI)   Watch this stock  
Find more results for DMPI
1.40
+0.09 (6.87%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.31 - 1.43
52 week 0.78 - 5.39
Open 1.31
Vol / Avg. 230,178.00/1.38M
Mkt cap 30.24M
P/E     -
Div/yield     -
EPS -0.68
Shares 21.60M
Beta 1,227.20
Inst. own 17%
Feb 12, 2018
Q2 2018 DelMar Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 14, 2017
Q1 2018 DelMar Pharmaceuticals Inc Earnings Call
Nov 13, 2017
Q1 2018 DelMar Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -95.66% -113.29%
Return on average equity -326.85% -
Employees 4 -
CDP Score - -

Address

999 Broadway W Suite 720
VANCOUVER, BC V5Z 1K5
Canada
+1-604-6295989 (Phone)
+1-604-6085685 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Officers and directors

Erich Mohr Ph.D. Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Saiid Zarrabian Interim President, Interim Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Scott Praill Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Dennis M. Brown Ph.D. Chief Scientific Officer, Director
Age: 66
Bio & Compensation  - Reuters
John K. Bell Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Jeffrey A. Bacha Director
Age: 48
Bio & Compensation  - Reuters
Lynda Sarah Cranston Independent Director
Age: 68
Bio & Compensation  - Reuters
Robert J. Toth Jr. Independent Director
Age: 53
Bio & Compensation  - Reuters